Acute Lymphoblastic Leukemia – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of ALL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.
Clarivate Epidemiology’s ALL forecast will answer the following questions:
- Of all people diagnosed with ALL, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALL over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 41 ALL patient populations, including the following:
- Second-line B-cell receptor-Abelson leukemia virus (BCR–ABL)-positive drug-treatable older adult population.
- Second-line BCR–ABL-negative drug-treatable older adult population.
- Second-line BCR–ABL-positive drug-treatable adolescent and young adult population.
- Second-line BCR–ABL-negative drug-treatable adolescent and young adult population.
- Second-line BCR–ABL-positive drug-treatable pediatric population.
- Second-line BCR–ABL-negative drug-treatable pediatric population.
- Third- and fourth-line BCR–ABL-positive drug-treatable adolescent and young adult population.
- Third- and fourth-line BCR–ABL-negative drug-treatable adolescent and young adult population.
- Third- and fourth-line BCR–ABL-positive drug-treatable older adult population.
- Third- and fourth-line BCR–ABL-negative drug-treatable older adult population.
- … and many more (details available upon request).
Note: Coverage may vary by country.
Table of contents
- Acute Lymphoblastic Leukemia - Epidemiology - Emerging Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of acute lymphoblastic leukemia)
- Diagnosed incident cases
- Diagnosed prevalent cases
- Age distribution
- BCR-ABL status
- Immunophenotype
- Precursor B-cell immunophenotype
- Drug-treatable and drug-treated populations
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.